AFFILIATIONS
1 Heidelberg Myeloma Center and GMMG Study Office, Department of Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
2 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany
3 Department of Internal Medicine II, Division of Hematology and Internal Medicine, Jena University Hospital, Jena, Germany
4 Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany
5 Coordination Centre for Clinical Trials (KKS), Medical Faculty, and Heidelberg University Hospital, Heidelberg, Germany
6 Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Cancer Research Laboratory of the Department of Internal Medicine III, Paracelsus Medical University, Salzburg, Austria
7 Department of Hematology, and Cell Therapy, Helios Clinic Berlin-Buch, Berlin, Germany
8 Coordination Centre for Clinical Trials (KKS), Medical Faculty, and Heidelberg University Hospital, Heidelberg, Germany
9 Clinic for Hematology, Oncology, and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany
10 Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany
11 Brüderkrankenhaus St. Josef, Paderborn, Germany
12 Heidelberg Myeloma Center and GMMG Study Office, Department of Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
13 Heidelberg Myeloma Center and GMMG Study Office, Department of Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
14 Department of Oncology and Hematology, Klinikum Oldenburg, University Medicine Oldenburg, Oldenburg, Germany
15 Clinic of Hematology, Oncology, Pneumology, Nephrology, and Diabetology, Medical University Lausitz - Carl Thiem, Cottbus, Germany
16 Department of Hematology and Medical Oncology, SLK-Clinics Heilbronn GmbH, Heilbronn, Germany
17 Department of Internal Medicine III, Hematology and Oncology, University Hospital, Regensburg, Germany
18 Department of Hematology, Oncology, Stem Cell Transplantation, and Palliative Medicine, Stuttgart Hospital, Stuttgart, Germany
19 Department of Internal Medicine II, Division of Integrated Psychosomatic Medicine, Würzburg University Hospital, Wurzburg, Germany
20 Department of Medicine II - Hematology and Oncology, Goethe-University, University Hospital, Frankfurt am Main, Germany
21 Heidelberg Myeloma Center and GMMG Study Office, Department of Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
22 Department of Hematology and Medical Oncology, Johanniter Hospital, Bonn, Germany
23 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany
24 Coordination Centre for Clinical Trials (KKS), Medical Faculty, and Heidelberg University Hospital, Heidelberg, Germany
25 Heidelberg Myeloma Center and GMMG Study Office, Department of Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
26 Department of Hematology, Oncology, and Palliative Care, Robert Bosch Hospital, Stuttgart, Germany
27 Department of Internal Medicine (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg, Germany
28 Heidelberg Myeloma Center and GMMG Study Office, Department of Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
29 Department of Internal Medicine, Hematology, Oncology, and Palliative Medicine, Vivantes Klinikum Neukölln, Berlin, Germany
30 Heidelberg Myeloma Center and GMMG Study Office, Department of Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
31 Department of Hematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
32 Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
33 Department of Oncology, Hematology, and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
34 Austrian Group for Medical Tumor Therapy (AGMT) GmbH, Salzburg, Austria
35 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany
36 Heidelberg Myeloma Center and GMMG Study Office, Department of Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
ABSTRACT
Introduction
Isatuximab (Isa) intravenous (IV; based on the GMMG-HD7 trial [NCT03617731]) and subcutaneous (SC) via the novel on-body injector (OBI) plus lenalidomide, bortezomib, and dexamethasone (RVd) are approved for patients (pts) with transplant-eligible newly diagnosed multiple myeloma (TE NDMM). SC delivery of Isa via the OBI offers shorter administration duration vs Isa IV and hands-free delivery. Here, we present the first results of the phase 3 GMMG-HD8/DSMM XIX (NCT05804032) trial on efficacy, safety and pt satisfaction evaluating the noninferiority of Isa SC OBI vs Isa IV plus RVd in pts with TE NDMM.
Methods
Pts were enrolled in 81 sites in Germany and Austria and randomized 1:1 to receive three 42-day cycles of Isa SC OBI (1400 mg) or Isa IV (10 mg/kg) plus RVd (R, 25 mg/day (D) orally (PO); V, 1.3 mg/m2 SC; d, 20 mg/D PO). Randomization was stratified according to revised International Staging System (R-ISS; I/II vs III vs not classified) and body weight (≤65.9 kg vs 66.0–85.0 kg vs >85.0 kg) categories. Primary objective was noninferiority of Isa SC compared to Isa IV regarding very good partial response or better (≥VGPR) rate after induction therapy, assessed in the per-protocol (PP) population. Key secondary objectives were noninferiority of rates of measurable residual disease negativity (MRD-) by next-generation sequencing (sensitivity 10-5; independent of IMWG criteria) after induction therapy in the PP population and superiority of pt-reported satisfaction with therapy score, assessed by the Cancer Therapy Satisfaction Questionnaire (CTSQ) in the intention-to-treat (ITT) population during induction therapy. Trial treatment ended after the first autologous stem cell transplant (ASCT). Date of the present analysis was July 22, 2026.
Results
From April 2023 to February 2025, 514 pts (ITT; safety: N=502; PP: N=452) were randomized (Isa SC OBI: N=256; Isa IV: N=258). Baseline characteristics were well balanced between arms. Median age was 61 years (range: 30–70) with Isa SC OBI and 61 years (35–70) with Isa IV. Median weight was 82 kg (range: 45–144) with Isa SC OBI and 80 kg (44–146) with Isa IV.
Post-induction ≥VGPR rate was 78.7% (95% CI: 72.7–83.9) with Isa SC OBI and 80.1% (95% CI: 74.4–85.0) with Isa IV (response rate ratio: 0.98). Noninferiority was met (P=.012). MRD- was 43.0% (95% CI: 36.4–49.8) with Isa SC OBI and 42.0% (95% CI: 35.6–48.6) with Isa IV. There was consistent improvement in pt satisfaction per CTSQ across all treatment cycles with greater improvement seen in cycles 2 and 3 (mean differences: 7.02–7.66) compared to cycle 1 (mean differences: 4.74–6.26).
All adverse events (AEs) during induction were similar in both arms (Isa SC OBI: 97.2%; Isa IV: 99.2%). Grade (G)≥3 AEs occurred less with Isa SC OBI (78.5%) vs Isa IV (83.9%). AEs leading to permanent discontinuation of Isa occurred in 3.2% of Isa SC OBI pts and 5.9% of Isa IV pts. The incidence of infusion-related reactions was lower with Isa SC OBI (all G: 1.6%; no G≥3) vs Isa IV (all G: 15.3%; G≥3: 2.0%). Injection-site reactions were reported in 9.7% of Isa SC OBI pts (G1/2: 9.3%; G≥3: 0.4%). G≥3 neutropenia was more common with Isa SC OBI (23.9%) than with IV (13.7%), while the incidence of G≥3 infections was similar (15.4% vs 14.9%, respectively). G≥3 peripheral neuropathy occurred in 6.1% Isa SC OBI and 9.0% Isa IV pts. Progressive disease occurred in 7 Isa SC OBI and 4 Isa IV pts until regular end of treatment after first ASCT. In total, 9 deaths were reported during treatment (3 Isa SC OBI and 6 Isa IV pts), with infection-related deaths in 4/9 pts. OBI device deficiencies were reported in 0.35% (9/2558) of SC injections.
Stem cell collection post induction was successful in 98.7% (222/225) of Isa SC OBI and 96.0% (218/227) of Isa IV pts starting mobilization therapy. Median number of CD34+ stem cells collected was 7.23 x 106 and 7.13 x 106 cells per kg in Isa SC OBI and Isa IV pts, respectively. Overall, 84.0% (215/256) Isa SC OBI and 82.6% (213/258) Isa IV pts proceeded to first ASCT. Detailed analyses on key secondary end points, response rates, PFS and OS will be presented at the meeting.
Conclusion
In this first phase 3 study comparing SC vs IV anti-CD38 therapy in pts with TE NDMM, noninferiority in ≥VGPR rates of Isa SC OBI vs Isa IV, plus RVd, was demonstrated with a manageable safety profile. A high OBI injection completion rate reaffirms Isa SC OBI as an innovative and convenient option for treating pts with MM.